Table 1.

Participant characteristics at baseline.

  Treatment Group 
ADA, n = 277nbDMARD, n = 148P
Age, yrs, mean (SD)52.0 (12.1)50.5 (12.6)0.24
Sex, male145 (52.3)64 (43.2)0.07
Race   
      White255 (92.1)136 (91.9)0.74
      Asian10 (3.6)8 (5.4) 
      Other12 (4.4)4 (2.7) 
Tobacco use a   
      Never smoked118 (43.9)80 (54.1)0.14
      Former smoker108 (40.1)48 (32.4) 
      Current smoker43 (16.0)20 (13.5) 
Employeda144 (52.4)95 (64.6)0.02
PsA duration, yrs, mean (SD)4.8 (6.6)4.1 (7.7)0.40
PsO duration, yrs, mean (SD)14.0 (13.0)12.8 (13.9)0.40
Family history of PsAa101 (36.6)64 (43.2)0.20
RF+a15 (5.5)5 (3.4)0.20
Morning stiffness, min/d, mean (SD)83.1 (98.2)61.8 (77.4)0.02
BSA affecteda, %   
      < 3150 (56.3)93 (64.5)0.15
      3–1077 (29.0)40 (27.8) 
      11–2023 (8.6)8 (5.6) 
      > 2016 (6.0)3 (2.1) 
Dominant PsA subtypea   
      Symmetric polyarthritis176 (68.2)79 (57.2)0.06
      Asymmetric oligoarthritis59 (22.9)48 (34.8) 
      Distal interphalangeal arthropathy7 (2.7)6 (4.3) 
      Spondylitis14 (5.4)5 (3.6) 
      Arthritis mutilans2 (0.8)0 (0.0) 
No. of prior/discontinued nbDMARDsb  < 0.001
      077 (27.8)73 (49.3) 
      191 (32.9)51 (34.5) 
      ≥ 2109 (39.4)24 (16.2) 
Medication use  NA
      ADA277 (100.0)NA 
      NSAIDs121 (43.7)82 (55.4) 
      nbDMARDs222 (80.1)148 (100.0) 
            Apremilast0 (0.0)2 (1.4) 
            AZA3 (1.1)2 (1.4) 
            CSA2 (0.7)0 (0.0) 
            Gold2 (0.7)0 (0.0) 
            HCQ53 (19.1)33 (22.3) 
            LEF29 (10.5)31 (20.9) 
            MTX182 (65.7)120 (81.1) 
            SSZ49 (17.7)34 (23.0) 
Enthesitisa77 (28.4)33 (23.4)0.28
Dactylitisa71 (26.2)53 (36.3)0.03
Morning stiffness, min/d, mean (SD)83.1 (98.2)61.8 (77.4)0.02
DAPSA28, mean (SD)39.3 (18.2)31.3 (16.4)< 0.001
DAS28, mean (SD)4.8 (1.2)4.3 (1.1)0.001
TJC28, mean (SD)8.9 (6.2)7.4 (6.6)0.02
SJC28, mean (SD)7.4 (5.0)5.9 (4.6)0.003
PGA (100-mm VAS), mean (SD)59.4 (19.5)51.0 (21.8)< 0.001
PtGA (100-mm VAS), mean (SD)56.1 (24.1)45.1 (24.7)< 0.001
Pain (100-mm VAS), mean (SD)58.5 (24.3)50.1 (24.0)0.002
HAQ-DI, mean (SD)1.1 (0.7)0.8 (0.6)< 0.001
SF-12 PCS34.7 (10.0)36.5 (10.8)0.24
SF-12 MCS43.8 (11.7)44.5 (10.8)0.69
ESR, mm/h, mean (SD)19.4 (17.8)16.2 (14.4)0.10
CRP, mg/L, mean (SD)16.2 (41.1)12.3 (19.4)0.23
  • Values are n (%) unless otherwise indicated.

  • aProportions based on patients with available data. Missing or unknown information for ADA- and nbDMARD-treated patients, respectively, were as follows: tobacco use (n = 8 and n = 0), employment status (n = 2 and n = 1) family history of PsA (n = 1 and n = 0), RF status (n = 3 and n = 0), BSA (n = 11 and n = 4), dominant PsA subtype (n = 19 and n = 10), enthesitis (n = 6 and n = 7), dactylitis (n = 6 and n = 2), morning stiffness (n = 12 and n = 7), DAPSA28 (n = 65 and n = 44), DAS28 (n = 49 and n = 33), TJC28 (n = 2 and n = 0), SJC28 (n = 2 and n = 1), PGA (n = 15 and n = 23), PtGA (n = 33 and n = 23), pain (n = 35 and n = 25), HAQ-DI (n = 34 and n = 23), SF-12 (n = 148 and n = 83), ESR (n = 87 and n = 49), and CRP (n = 36 and n = 23).

  • b Excluding nbDMARDs initiated prior to baseline that were ongoing at baseline. ADA: adalimumab; AZA: azathioprine; BSA: body surface area; CRP: C-reactive protein; CSA: cyclosporine A; DAPSA: Disease Activity Index for Psoriatic Arthritis in 28 joints; DAS28: Disease Activity Score in 28 joints; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire–Disability Index; HCQ: hydroxychloroquine; LEF: leflunomide; MCS: mental component summary; PGA: physician global assessment; MTX: methotrexate; NA: not applicable; NSAID: nonsteroidal antiinflammatory drug; nbDMARD: nonbiologic disease-modifying antirheumatic drug; PCS: physical component summary; PsA: psoriatic arthritis; PsO: psoriasis; PtGA: patient global assessment; RF: rheumatoid factor; SF-12: 12-item Short Form Health Survey; SJC28: swollen joint count in 28 joints; SSZ: sulfasalazine; TJC28: tender joint count in 28 joints; VAS: visual analog scale.